Sign in
← Compounds

Fezolinetant (Veozah)

on-label Rx · comparatorFDA-approved

NK3R antagonism (thermoregulatory)

Summary

NK3R antagonist — the validated NON-hormonal therapy for menopausal vasomotor symptoms. Not a peptide; the comparator no peptide beats for hot flashes.

How it works

  • Neurokinin-3 receptor antagonism in the thermoregulatory center

Dosing

  • unit: mg
    frequency: daily
    standard dose: 45
    administration route: Oral

Cycling

  • Continuous

Side effects

common: ["Headache","Abdominal pain"]
warnings: ["Hepatotoxicity — LFT monitoring"]

Verified citations

3 · PubMed-checked
  • Fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1).clinicalPMID 36924778 ↗
  • Efficacy and Safety of Fezolinetant in Vasomotor Symptoms Associated With Menopause: Phase 3 RCT.clinicalPMID 36734148 ↗
  • Fezolinetant in the treatment of vasomotor symptoms associated with menopause.reviewPMID 33724119 ↗

Used for

Legal / compounding

FDA-approved

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.